NovaSure impedance controlled system for endometrial ablation: three-year follow-up on 107 patients

Non-randomised trial OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-30 ⓘ

This three-year follow-up study evaluated 107 patients who underwent endometrial ablation using the NovaSure impedance-controlled system, reporting on patient outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: This study was undertaken to assess the safety, efficacy, and data durability of the NovaSure ablation at 3 years after the procedure in women with menorrhagia secondary to dysfunctional uterine bleeding (DUB). STUDY DESIGN: A prospective, single-arm, observational pilot study (Canadian Task Force classification II-1) was carried out at a specialized center for gynecologic endoscopy with 107 premenopausal women with menorrhagia secondary to DUB. NovaSure ablation was performed in 107 patients. Pictorial Blood loss Assessment Chart diary sampling was used to assess menstrual blood loss. Ablation was performed without any type of endometrial pretreatment. RESULTS: No intraoperative or postoperative complications were observed. Treatment time averaged 94 seconds; 65% of the patients reported amenorrhea. Hysterectomy was avoided in 97.2% of patients at 3-year follow-up. CONCLUSION: Long-term clinical results demonstrate that the NovaSure system is a safe and effective method for treatment of women with menorrhagia secondary to DUB, yielding high amenorrhea and success rates, with low re-treatment rates.

My notes (saved in your browser only)

MeSH descriptors

Catheter Ablation Menorrhagia Adult Catheter Ablation Female Follow-Up Studies Humans Menorrhagia Menorrhagia Middle Aged Pilot Projects Postoperative Complications Prospective Studies Treatment Outcome

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (3)

References (23)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-14T06:04:04.317202+00:00
pubmed
last seen: 2026-10-08T21:02:47.667321+00:00
unpaywall
last seen: 2026-10-25T06:24:14.523685+00:00
License: CC0 · commercial use OK